CRM1 as a new therapeutic target for non-Hodgkin lymphoma

Leukemia Research

Volumn 39, Issue 1, 2015, Pages 38-46

  Han, Xiaohong ^a   Wang, Jianfei ^a   Shen, Yinchen ^a   Zhang, Ningning ^a   Wang, Shuai ^a   Yao, Jiarui ^a   Shi, Yuankai ^a  

^a CANCER HOSPITAL   (China)

Author keywords

CRM1; CRM1 inhibitor; Non Hodgkin lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; EXPORTIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KPT 185; KPT 276; MESSENGER RNA; SURVIVIN; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; ACRYLIC ACID DERIVATIVE; CELL RECEPTOR; EXPORTIN 1 PROTEIN; KARYOPHERIN; KPT-185; KPT-276; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; ENZYME DEGRADATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; JEKO 1 CELL LINE; MALE; MOUSE; NON-HODGKIN LYMPHOMA CELL LINE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; JURKAT CELL LINE; LYMPHOMA, NON-HODGKIN; METABOLISM; MULTICENTER STUDY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROTEIN DEGRADATION; SCID MOUSE;

ACRYLAMIDES; ACRYLATES; ANIMALS; ANTINEOPLASTIC AGENTS; CASPASES; CELL CYCLE CHECKPOINTS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JURKAT CELLS; KARYOPHERINS; LYMPHOMA, NON-HODGKIN; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; PROTEOLYSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920366106     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.10.003     Document Type: Article

References (41)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Shankland K.R., Armitage J.O., Hancock B.W. Non-Hodgkin lymphoma. Lancet 2012, 380(9844):848-857.
3. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83(8):1021-1032.
4. Fornerod M., Ohno M., Yoshida M., Mattaj I.W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997, 90(6):1051-1060.
5. Fukuda M., Asano S., Nakamura T., Adachi M., Yoshida M., Yanagida M., et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997, 390(6657):308-311.
6. Ossareh-Nazari B., Bachelerie F., Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 1997, 278(5335):141-144.
7. Stade K., Ford C.S., Guthrie C., Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997, 90(6):1041-1050.
8. Xu D., Farmer A., Chook Y.M. Recognition of nuclear targeting signals by karyopherin-beta proteins. Curr Opin Struct Biol 2010, 20(6):782-790.
9. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999, 18(6):1660-1672.
10. O'Brate A., Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code?. Drug Resist Updat 2003, 6(6):313-322.
11. Huang T.T., Kudo N., Yoshida M., Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci U S A 2000, 97(3):1014-1019.
12. Rodriguez J.A., Span S.W., Ferreira C.G., Kruyt F.A., Giaccone G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 2002, 275(1):44-53.
13. Li F., Yang J., Ramnath N., Javle M.M., Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int J Cancer 2005, 114(4):509-512.
14. Stauber R.H., Mann W., Knauer S.K. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007, 67(13):5999-6002.
15. Yashiroda Y., Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 2003, 10(9):741-748.
16. Turner J.G., Sullivan D.M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 2008, 15(26):2648-2655.
17. Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E.P., Wolff B., et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 1999, 96(16):9112-9117.
18. Koster M., Lykke-Andersen S., Elnakady Y.A., Gerth K., Washausen P., Höfle G., et al. Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp Cell Res 2003, 286(2):321-331.
19. Mutka S.C., Yang W.Q., Dong S.D., Ward S.L., Craig D.A., Timmermans P.B., et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009, 69(2):510-517.
20. Murakami N., Ye Y., Kawanishi M., Aoki S., Kudo N., Yoshida M., et al. New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg Med Chem Lett 2002, 12(20):2807-2810.
21. Van Neck T., Pannecouque C., Vanstreels E., Stevens M., Dehaen W., Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 2008, 16(21):9487-9497.
22. Sakakibara K., Saito N., Sato T., Suzuki A., Hasegawa Y., Friedman J.M., et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011, 118(14):3922-3931.
23. Newlands E.S., Rustin G.J., Brampton M.H. Phase I trial of elactocin. Br J Cancer 1996, 74(4):648-649.
24. Lapalombella R., Sun Q., Williams K., Tangeman L., Jha S., Zhong Y., et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012, 120(23):4621-4634.
25. Ranganathan P., Yu X., Na C., Santhanam R., Shacham S., Kauffman M., et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012, 120(9):1765-1773.
26. Inoue H., Kauffman M., Shacham S., Landesman Y., Yang J., Evans C.P., et al. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol 2013, 189(6):2317-2326.
27. Azmi A.S., Aboukameel A., Bao B., Sarkar F.H., Philip P.A., Kauffman M., et al. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 2013, 144(2):447-456.
28. Zhang K., Wang M., Tamayo A.T., Shacham S., Kauffman M., Lee J., et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 2013, 41(1):67-78. e64.
29. Etchin J., Sun Q., Kentsis A., Farmer A., Zhang Z.C., Sanda T., et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2013, 27(1):66-74.
30. Etchin J., Sanda T., Mansour M.R., Kentsis A., Montero J., Le B.T., et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013, 161(1):117-127.
31. Tai Y.T., Landesman Y., Acharya C., Calle Y3, Zhong MY1, Cea M1 et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 2014, 28(1):155-165.
32. Goldberg A.L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007, 35(Pt 1):12-17.
33. Eyre T.A., Collins G.P. Current treatment and future prospects for peripheral T-cell lymphoma. Drugs Today (Barc) 2013, 49(10):631-646.
34. Lunning M.A., Horwitz S. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?. Curr Treat Options Oncol 2013, 14(2):212-223.
35. Dey A., Tergaonkar V., Lane D.P. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov 2008, 7(12):1031-1040.
36. Chakravarti A., Zhai G.G., Zhang M., Malhotra R., Latham D.E., Delaney M.A., et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004, 23(45):7494-7506.
37. Lu B., Mu Y., Cao C., Zeng F., Schneider S., Tan J., et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004, 64(8):2840-2845.
38. Park E., Gang E.J., Hsieh Y.T., Schaefer P., Chae S., Klemm L., et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011, 118(8):2191-2199.
39. Knauer S.K., Mann W., Stauber R.H. Survivin's dual role: an export's view. Cell Cycle 2007, 6(5):518-521.
40. Stauber R.H., Rabenhorst U., Rekik A., Engels K., Bier C., Knauer S.K. Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal. Traffic 2006, 7(11):1461-1472.
41. Chan K.S., Wong C.H., Huang Y.F., Li H.Y. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 2010, 1:e57.